** Shares of Telix Pharmaceuticals TLX.AX fall 6% to A$26.86, their lowest since April 14
** Stock among the biggest percentage losers in the benchmark ASX200 index .AXJO
** Biotech firm says that the U.S. Food and Drug Administration (FDA) has refused to approve its new drug application for Pixclara, an investigational agent for imaging glioma
** FDA has requested additional clinical evidence to progress the application, stating that the application cannot be approved in its current form - TLX
** Stock fell as much as 9.3% earlier in the day, marking its worst intraday drop since April 7
** Stock up 9.7% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。